Article

B + L, TPV join forces

Bausch + Lomb and Technolas Perfect Vision GmbH (TPV) plan to globally distribute a femtosecond laser capable of performing both cataract and refractive procedures on one platform.

Rochester, NY-Bausch + Lomb (B+L) and Technolas Perfect Vision GmbH (TPV) plan to distribute globally a femtosecond laser capable of performing both cataract and refractive procedures on one platform.

TPV was established in 2009 through a joint venture between B+L and 20/10 Perfect Vision AG to develop advanced refractive and cataract technologies. Under the terms of the agreement, TPV will develop and manufacture its laser system from its facilities in Munich, Germany, and will service the product through its current worldwide service organization. B+L Surgical will globally distribute the laser.

Financial terms were not disclosed. TPV will continue to commercialize its refractive portfolio.

“Femtosecond laser technology for cataract procedures promises to be one of the most significant clinical advances in cataract surgery in 40 years,” said Robert E. Grant, chief executive officer and president of B+L Surgical. “The TPV femtosecond laser platform, which uniquely supports refractive and cataract procedures, is a natural complement to our portfolio of cataract products. This is the first of many new technologies we are pursuing focused on enhancing a physician’s ability to improve patient outcomes.”

Commercialization is expected to begin in the second half of this year. TPV previously announced that it has filed for FDA 510(k) clearance for the laser.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
© 2025 MJH Life Sciences

All rights reserved.